Affordable Access

deepdyve-link
Publisher Website

Mitogen-activated protein kinases as therapeutic targets in osteoarthritis.

Authors
  • Loeser, Richard F
  • Erickson, Elizabeth A
  • Long, David L
Type
Published Article
Journal
Current Opinion in Rheumatology
Publisher
Ovid Technologies (Wolters Kluwer) - Lippincott Williams & Wilkins
Publication Date
Sep 01, 2008
Volume
20
Issue
5
Pages
581–586
Identifiers
DOI: 10.1097/BOR.0b013e3283090463
PMID: 18698181
Source
Medline
License
Unknown

Abstract

MAP kinase inhibition has the potential to slow disease progression in osteoarthritis and also might reduce pain; however, safety concerns have limited the use of general MAP kinase inhibitors in humans. Further understanding of the function of specific isoforms of the MAP kinases as well as upstream and downstream effectors may lead to the development of more specific inhibitors with less toxicity that could eventually be used as structure-modifying drugs for osteoarthritis.

Report this publication

Statistics

Seen <100 times